Search
Acrivastine
go.drugbank.com/drugs/DB09488ApprovedAs an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension
Mixtures: DUACT 8 MG/60 MG KAPSÜL, 30 ADETGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
Methyl bacteriopurpurinimide
go.drugbank.com/drugs/DB17134InvestigationalSynonyms: 9,12-imino-2,21-metheno-7,4:14,17-dinitrilo-4h-pyrido(4,3-b)azacyclononadecine-16-propanoic acid, 10-(1-butoxyethyl)-19-butyl-5-ethyl-1,5,6,15,16,18,19,20-octahydro-6,11,15,22-tetramethyl-18,20-dioxo-,, (5r,6r,15s,16s)-Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences. … [L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided
Sodium cation
go.drugbank.com/drugs/DB14516InvestigationalMixtures: POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETLI, POLİFLEKS LAKTATLI RİNGER IV İNFÜZYON İÇİN ÇÖZELTİ, 100 ML (PVC TORBA) SETSİZRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-OneCategories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesFlorquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … [L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease
Synonyms: 6-fluoro-3-(1h-pyrrolo(2,3-c)pyridin-1-yl)isoquinolin-5-amine, 5-isoquinolinamine, 6-(fluoro-18f)-3-(1h-pyrrolo(2,3-c)pyridin-1-yl)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnSimilarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: Menjugate 10 Mikrogramm Injektionssuspension, MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADETGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … [L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. [ciprofloxacin] - while being structurally and pharmacologically distinct.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates